// App-Quantinova.ai

TPS261 : A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).

Researchers

Presenter

  • Yelena Y. Janjigian

Principal Investigators

  • Natasha Viglianti

  • Feng Liu

  • Ariadna Mendoza-Naranjo

  • Liz Croydon

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Astex Pharmaceutical, Inc., Cambridge, United Kingdom.

  • AstraZeneca Pharmaceuticals, Gaithersburg, MD

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Gastric Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Adrucil injection

  • Capecitabine

  • Trastuzumab

  • Oxaliplatin

  • Durvalumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04379596

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved